Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

May 07, 2025 07:00 ET | Source: Immunocore Holdings plc

Immunocore reports first quarter financial results and provides a business update

Immunocore reports first quarter financial results and provides a business update KIMMTRAK® (tebentafusp-tebn) net revenues of $93.9 million in Q1 2025, growing by 33% year-over-year On track for...
February 26, 2025 07:00 ET | Source: Immunocore Holdings plc

Immunocore reports fourth quarter and full year 2024 financial results and provides a business update

KIMMTRAK (tebentafusp) Q4 net sales of $84.1 million and $310.0 million for full year 2024; continued growth expected in 2025 Executing on KIMMTRAK lifecycle management with two Phase 3 trials...
December 11, 2024 07:00 ET | Source: Immunocore Holdings plc

EORTC and Immunocore announce enrolment of first patient onto the only active Phase 3 adjuvant trial in uveal melanoma

ATOM is the only active Phase 3 trial for adjuvant treatment of uveal melanoma The trial will assess whether adjuvant treatment with tebentafusp can decrease the risk of relapse, compared to...
March 12, 2021 04:13 ET | Source: Research and Markets

4 Report Package: "Drug the Undruggable" Technologies Bundle - Four Full Reports for the Price of Two

Dublin, March 12, 2021 (GLOBE NEWSWIRE) -- The "Report Package: "Drug the Undruggable" Technologies" report has been added to ResearchAndMarkets.com's offering. This report package includes four...